IL-2 have in pre-clinical studies shown therapeutic efficacy by restoring NK cell receptor expression and bolster NK cell cytotoxicity against autologous AML blasts in vitro (48), but clinical studies evaluating IL-2 monotherapy in AML and MDS have been disappointing (154–156). This evidence concerns the gene IL2 and acute myeloid leukemia.